Super-Transactivation TP53 Variant in the Germline of a Family with Li–Fraumeni Syndrome

Human Mutation

Volumn 37, Issue 9, 2016, Pages 889-892

  Id Said, Badr ^a,b,c   Kim, Han ^a,c   Tran, James ^a,b,c   Novokmet, Ana ^a,c   Malkin, David ^a,b,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

gene therapy; Li Fraumeni Syndrome; p53; single nucleotide polymorphism

Indexed keywords

PROTEIN P53;

ARTICLE; DNA RESPONSIVE ELEMENT; EXON; FAMILIAL CANCER; GENETIC VARIABILITY; HUMAN; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSACTIVATION; TUMOR REGRESSION;

EID: 85027929002     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.23025     Document Type: Article

References (15)

1. Bougeard G, Seboue R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J, Brugieres L, Chompret A, de Paillerets BB, Stoppa-Lyonnet D, Bonaiti-Pellie C, et al. 2008. Molecular basis of the Li–Fraumeni syndrome: an update from the French LFS families. J Med Genet 45:535–538.
2. Chen GX, Zhang S, He XH, Liu SY, Ma C, Zou XP. 2014. Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. OncoTargets Ther 7:1901–1909.
3. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. 2003. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365.
4. Fang S, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson CD, Bachinski LL, Strong LC, Amos CI. 2010. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations. PloS One 5:e10813.
5. Han DM, Huang ZG, Zhang W, Yu ZK, Wang Q, Ni X, Chen XH, Pan JH, Wang H. 2003. Effectiveness of recombinant adenovirus p53 injection on laryngeal cancer: phase I clinical trial and follow up. Zhonghua Yi Xue Za Zhi 83:2029–2032. Chinese
6. Levine AJ. 1997. p53, the Cellular Gatekeeper for Growth and Division. Cell 88:323–331.
7. Malkin D, Li F, Fraumeni J, Nelson C, Kim D, Kassel J, Gryka M, Bischoff F, Tainsky M. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233–1238.
8. Marcel V, Palmero EL, Falagan-Lotsch P, Martel-Planche G, Ashton-Prolla P, Olivier M, Brentani RR, Hainait P, Achatz MI. 2009. TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. J Med Genet 46:766–772.
9. Petijean A, Mathe E, Kato S, Ishika C, Tavtigian SV, Hainaut P, Olivier M. 2007. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622–629.
10. Senzer N, Nemunaitis J, Nemunaitis M, Lamont J, Gore M, Gabra H, Eeles R, Sodha N, Lynch FJ, Zumstein LA, Menander KB, Sobol RE, Chada S. 2007. p53 therapy in a patient with Li–Fraumeni Syndrome. Mol Cancer Ther 6:1478–1482.
11. Shimada H, Matsubara H, Shiratori T, Shimizu T, Miyazaki S, Okazumi S, Nabeya Y, Shuto K, Hayashi H, Tanizawa T, Nakatani Y, Nakasa H, Kitada M, Ochiai T. 2006. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer Sci 97:554–561.
12. Soussi T, Béroud C. 2003. Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum Mutat 21:192–200.
13. Wasserman JD, Novokmet A, Eichler-Jonsson C, Ribeiro RC, Rodriguez-Gallindo C, Zamberri GP, Malkin D. 2015. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a Children's Oncology Group study. J Clin Oncol 6:602–609.
14. Yoo GH, Moon J, Leblanc M, Lonardo F, Urba S, Kim H, Hanna E, Tsue T, Valentino J, Ensley J, Wolf G. 2009. A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Arch Otolaryngol Head Neck Surg 135:869–874.
15. Zhang SW, Xiao SW, Liu CQ, Sun Y, Su X, Li DM, Xu G, Cai Y, Zhu GY, Xu B, Lu YY. 2003. Treatment of head and neck squamous cell carcinoma by recombinant adenovirus-p53 combined with radiotherapy: a phase II clinical trial of 42 cases. Zhonghua Yi Xue Za Zhi 83:2023–2028. Chinese.